Method for evaluating gastric mucosal state by quantifying helicobacter pylori antigen in feces

Abstract

It is intended to provide a method for evaluating the gastric mucosal state which can be conveniently carried out while loading little burden on a subject, shows missing cases at an extremely low ratio, and enables detailed classification of not only the gastric mucosal states with the pathological severity but also the risk of gastric cancer and the risk thereof in future. It is also intended toprovide a method for quantifying Helicobacter pylori cells occurring in the stomach in relation to the judgment of various pathological conditions. The above-described problems can be solved by a method for evaluating the gastric mucosal state of a subject by using a quantitative measurement value of Helicobacter pylori antigen occurring in the feces of the subject as an indication and a method ofquantifying Helicobacter pylori cells occurring in the stomach of the subject.

Description

technical field [0001] The present invention relates to a method for judging the state of gastric mucosa and a method for quantifying the amount of Helicobacter pylori present in the stomach by using the quantitative measurement value of Helicobacter pylori antigen present in feces as an index. Background technique [0002] Helicobacter pylori (Helicobacter pylori, hereinafter referred to as "Helicobacter pylori", "Hp", or "pylori", etc.) is a spiral Gram-negative bacterium that exists in the human gastric mucosa. The infection rate of Helicobacter pylori in humans tends to increase with age, and it is said to reach 70 to 80% in middle-aged and elderly people. [0003] In recent years, it has been considered that when a healthy stomach is infected with Helicobacter pylori, the gastric mucosa first exhibits tissue inflammation, and then the inflammation gradually intensifies (active gastritis), and soon becomes a state where gastric mucosa atrophy (atrophic gastritis) coexist...

AI Technical Summary

Problems solved by technology

X-ray examination is effectively used to detect early gastric cancer, but there are many missed cases and it cannot be used to diagnose the risk of gastric cancer in the future. Therefore, it is necessary to use it together with other diagnostic methods such as pepsinogen method for accurate diagnosis

Although the pepsinogen method is simple, in addition to a certain proportion of missed cases, there are still gastric cancer cases that cannot be found when it is used together with X-ray examination. In addition, it cannot predict the risk rate of gastric cancer or the risk of future gastric cancer. The degree of rate is subdivided, and the type of cancer (undifferentiated cancer, differentiated cancer, etc.) cannot be judged

In addition, although endoscopic examination can accurately diagnose not only gastric cancer but also the state of the gastric mucosa with a high risk of gastric cancer, there is a problem that it is not suitable for the examination because of the heavy burden on the subject and the high cost. Disadvantages of initial screening of groups including many healthy people such as health checkups (see Non-Patent Document 4)

[0010] In addition, in the above-mentioned method for diagnosing atrophic gastritis by detecting pepsinogen I, gastrin, and Helicobacter pylori infection markers, although it is mentioned that the risk of cancer is diagnosed (see Patent Document 1), it does not Specific examples of using Helicobacter pylori antigens as markers for Helicobacter pylori infection are described, and no studies have been conducted on the determination of the type of cancer (undifferentiated cancer, differentiated cancer, etc.)

Images